Clinical validation HepQuant is actively presenting multiple studies at major liver-focused conferences (EASL 2026, The Liver Meeting 2025, MASH-TAG 2025) to demonstrate the clinical and research value of the HepQuant DuO test and Disease Severity Index, signaling a strong case for adoption in hepatology practices.

Noninvasive liver testing The DuO test provides noninvasive, quantitative assessment of liver function and portal-systemic shunting, enabling clinicians to guide decisions about invasive procedures, monitor treatment response, and predict progression—a compelling value proposition for specialty clinics and referral networks.

Clinical adoption momentum Ongoing expansion of DuO test availability to liver specialists in Colorado and ongoing conference-driven dissemination indicate growing market reach and increasing demand among hepatology practices for noninvasive diagnostic tools.

Strategic partnerships Leveraging a tech stack that includes Salesforce, WordPress, Shopify, and cloud hosting suggests capacity for scalable sales enablement, patient/funder engagement, and e-commerce-style ordering or access portals, which can be exploited to accelerate sales cycles and cluster-clinics deals.

Funding and growth potential Reported revenue range of one to ten million USD and active investor-grade research activity imply a scalable business with room to expand payer coverage, hospital networks, and international conferences to drive increased adoption and recurring revenue.